NCT01520987

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 105 (actual)
• Sponsor: Bial - Portela C S.A. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To assess the pharmacokinetics of BIA 9-1067 in healthy Japanese subjects

Detailed description

Randomized, double-blind, placebo-controlled, multiple ascending dose, parallel-group, pharmacokinetic (PK) and pharmacodynamic (PD) study

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	BIA 9-1067	5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
DRUG	Placebo	once-daily

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2012-01-30
• Last updated: 2016-06-20
• Results posted: 2016-06-20

Locations

1 site across 1 country: United States